QULIPTA™ (atogepant) Now Approved by Health Canada for the Preventive Treatment of Chronic Migraine in Adults
- QULIPTA is now the first and only oral calcitonin gene-related peptide (CGRP) receptor antagonist (gepant) approved to prevent migraine across all frequencies, including episodic and chronic.
- Expanded indication provides an additional treatment option for those with chronic migraine whose frequent disabling attacks negatively impact performance of daily activities.
- Approval was based on a pivotal Phase 3 clinical trial that demonstrated statistically significant reduction from baseline in mean monthly migraine days.
-
AbbVie
"QULIPTA has been helping thousands of Canadians living with episodic migraine since
QULIPTA's expanded chronic migraine indication is based on the pivotal Phase 3 PROGRESS trial evaluating QULIPTA 60 mg once daily in adult patients with chronic migraine, which met its primary endpoint of statistically significant reduction of -6.9 from baseline in mean monthly migraine days compared to placebo of -5.1 across the 12-week treatment period.2 The average monthly migraine days (MMDs) for patients at baseline during the clinical trial was 19.2.
"Chronic migraine is incredibly debilitating for my patients. It makes day-to-day activities often unbearable, and isolates you from friends, family, and work," says Dr
QULIPTA blocks CGRP through a once-daily dose and is available in three strengths for the preventive treatment of episodic migraine – 10 mg, 30 mg and 60 mg. Only the 60 mg dose of QULIPTA is indicated for the preventive treatment of chronic migraine. The overall safety profile of QULIPTA is consistent with the episodic migraine patient population, with the most common adverse events including nausea, constipation, diarrhoea, and fatigue.1
"Bringing new migraine-specific medications to Canadians living with migraine is critical as so many have yet to find the relief they seek," says
Migraine is a complex neurological disease with recurrent attacks that lasts 4-72 hours. It can be defined by symptoms such as moderate to severe pain intensity, nausea, vomiting, photophobia and phonophobia.3 An estimated 2.7 million Canadians are reported diagnosed with migraine, however the number of people living with migraine is much higher.4 Episodic migraine is characterized as having less than 15 headache days per month, while 15 headache days or more per month, is considered chronic.5
QULIPTA (atogepant) is the first and only oral, small-molecule calcitonin gene-related peptide (CGRP) receptor antagonist (gepant) specifically developed for the preventive treatment of episodic and chronic migraine. QULIPTA is an orally administered, small-molecule, selective calcitonin gene-related peptide (CGRP) receptor antagonist that blocks the binding of the CGRP to its receptor. CGRP is a neuropeptide that may play a role in migraine pathophysiology.1
For important safety information, please consult the QULIPTA Product Monograph .
At
For more information on
|
1 AbbVie Canada. QULIPTA Product Monograph. |
|
2 AbbVie. Data on File: ABVRRTI73750 |
|
3
|
|
4 Ramage-Morin P., & Gilmour, H. (2014). Prevalence of migraine in the Canadian household population. Health Reports, 25(6): 10-16. https://www150.statcan.gc.ca/n1/en/pub/82-003-x/2014006/article/14033-eng.pdf?st=CSyp19VF. Accessed |
|
5 Migraine |
SOURCE